Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) Revenue (2016 - 2024)

Trinity Biotech's Revenue history spans 16 years, with the latest figure at $15.9 million for Q4 2024.

  • On a quarterly basis, Revenue rose 18.09% to $15.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $61.6 million, a 8.31% increase, with the full-year FY2025 number at $43.8 million, down 28.87% from a year prior.
  • Revenue hit $15.9 million in Q4 2024 for Trinity Biotech, up from $15.2 million in the prior quarter.
  • Over the last five years, Revenue for TRIB hit a ceiling of $32.8 million in Q4 2020 and a floor of $13.4 million in Q4 2023.
  • Historically, Revenue has averaged $18.8 million across 5 years, with a median of $15.8 million in 2022.
  • The widest YoY moves for Revenue: up 61.28% in 2021, down 40.41% in 2021.
  • Tracing TRIB's Revenue over 5 years: stood at $32.8 million in 2020, then plummeted by 40.41% to $19.5 million in 2021, then decreased by 19.46% to $15.7 million in 2022, then dropped by 14.61% to $13.4 million in 2023, then increased by 18.09% to $15.9 million in 2024.
  • Business Quant data shows Revenue for TRIB at $15.9 million in Q4 2024, $15.2 million in Q3 2024, and $15.8 million in Q2 2024.